---
document_datetime: 2024-08-22 10:42:05
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tremelimumab-astrazeneca-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tremelimumab-astrazeneca-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.0743161
conversion_datetime: 2025-12-21 12:08:30.343581
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                    | Opinion/ Notification 1 issued on in the name product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IG/1659              | A.5.a - Administrative change - Change and/or address of a manufacturer/importer responsible for batch release Medicinal | 04/09/2023                                              |                                             | Annex II and PL                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

Tremelimumab AstraZeneca Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->